South Korea parliament votes for impeachment of President ParkWorld December 09, 10:18
Lavrov says Moscow is uncertain whether Iraqi Al-Qaim was bombed on purposeRussian Politics & Diplomacy December 09, 9:05
US Congress votes to make Magnitsky Act applicable to other statesWorld December 09, 8:18
Analysts assume Trump poised to improve ties with RussiaWorld December 09, 8:12
UN envoy on Syria suggests resumption of intra-Syrian talksWorld December 09, 6:42
US Senate prohibits defense cooperation with RussiaMilitary & Defense December 09, 4:55
Russia and Cuba sign defense cooperation program until 2020Military & Defense December 09, 3:26
Putin jokingly suggests Russia should develop teleportationScience & Space December 09, 2:07
Russian investigators conduct searches across Russia over doping casesSport December 09, 1:52
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.